Internal Medicine, Medical Oncology · Estero, FL
NPI
1699194928
Since 2014
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
2
Medicare group memberships
Hospitals
3
Hospital affiliations
8440 Murano del Lago Dr
Estero, FL, 34135
Phone (239) 221-5402
Groups this clinician bills Medicare through
Medicare paid, 2024
$9.5M
463,178 services
Medicare patients, 2024
1,334
Average age 76
Drug cost, 2024
$11.0M
2,472 prescriptions
Company payments, 2025
$6,184
From 35 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Ahsan U Shah was code Q0138 (injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)), 54,060 times for 69 patients. In total Ahsan U Shah billed 463,178 services in 174 codes, and Medicare paid $9.5M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-07-24.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|
| Q0138 Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 54,060 | 69 | $0.28 | $15K |
| J1756 Injection, iron sucrose, 1 mg | Office | 38,300 | 63 | $0.18 | $6,779 |
| J9271 Injection, pembrolizumab, 1 mg | Office | 34,800 | 46 | $44.57 | $1.6M |
| J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 22,320 | 18 | $38.42 | $858K |
| Q5110 Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram | Office | 19,680 | 18 | $0.22 | $4,277 |
| J0185 Injection, aprepitant, 1 mg | Office | 17,420 | 47 | $1.33 | $23K |
| J9025 Injection, azacitidine, 1 mg | Office | 17,300 | 18 | $0.31 | $5,309 |
| J0885 Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 16,920 | 65 | $6.43 | $109K |
| J0897 Injection, denosumab, 1 mg | Office | 16,860 | 77 | $20.65 | $348K |
| J9263 Injection, oxaliplatin, 0.5 mg | Office | 11,306 | 14 | $0.06 | $631 |
| J1434 Injection, fosaprepitant (focinvez), 1 mg | Office | 9,000 | 20 | $2.28 | $21K |
| J1569 Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | Office | 8,782 | 29 | $35.38 | $311K |
| J9267 Injection, paclitaxel, 1 mg | Office | 7,193 | 15 | $0.08 | $574 |
| Q5106 Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | Office | 6,940 | 21 | $5.85 | $41K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 4,447 | 96 | $0.09 | $401 |
By year: 2022 $4.5M for 322,027 services; 2023 $6.0M for 330,265 services; 2024 $9.5M for 463,178 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 4,147 | 976 | $7.61 | $32K |
| 36415 Venipuncture Blood Collection | 3,544 | 952 | $8.65 | $31K |
| 81003 Clinical Chemistry | 97 | 35 | $2.20 | $213 |
| 85045 Blood Count | 21 | 20 | $3.91 | $82.11 |
Medicare prescription drug claims, 2024
In 2024, the drug Ahsan U Shah prescribed most often to Medicare patients was Revlimid (Lenalidomide), with 149 prescriptions and refills. In total Ahsan U Shah wrote 2,472 Medicare prescriptions that cost $11.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Revlimid Lenalidomide | 149 | 151 | 20 | $2.4M |
| Acyclovir Generic | 124 | 183 | 39 | $1,431 |
| Anastrozole Generic | 119 | 302 | 34 | $2,029 |
| Eliquis Apixaban | 105 | 120 | 21 | $70K |
| Prochlorperazine Maleate Generic | 87 | 93 | 55 | $1,706 |
| Brukinsa Zanubrutinib | 86 | 86 | 11 | $1.2M |
| Xtandi Enzalutamide | 85 | 85 | 12 | $1.2M |
| Prednisone Generic | 77 | 95 | 28 | $424 |
| Oxycodone Hcl Generic | 69 | 69 | 24 | $1,426 |
| Levothyroxine Sodium Generic | 69 | 118 | 25 | $443 |
| Hydroxyurea Generic | 65 | 141 | 19 | $1,845 |
| Dexamethasone Generic | 62 | 77 | 23 | $1,117 |
| Allopurinol Generic | 61 | 105 | 24 | $348 |
| Ondansetron Odt Ondansetron | 58 | 58 | 35 | $1,349 |
| Letrozole Generic | 51 | 147 | 21 | $2,157 |
Brand drugs: - claims; generic drugs: 1,580 claims; opioid claims: 197.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Ahsan U Shah $6,184 ($6,184 in general payments such as food, travel and fees) from 35 companies. The largest payer was Partner Therapeutics, Inc. with $3,243.
| Company | Payments | Amount |
|---|---|---|
| Partner Therapeutics, Inc. | 8 | $3,243 |
| Merck Sharp & Dohme LLC MRK | 11 | $315 |
| Pfizer Inc. PFE | 13 | $260 |
| Gilead Sciences, Inc. GILD | 11 | $225 |
| Celgene Corporation BMY | 7 | $183 |
| E.R. Squibb & Sons, L.L.C. BMY | 9 | $180 |
| Daiichi Sankyo Inc. 4568.T | 7 | $162 |
| Novartis Pharmaceuticals Corporation NVS | 8 | $161 |
| AstraZeneca Pharmaceuticals LP AZN | 6 | $139 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 5 | $131 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.